New-onset diabetes mellitus after pediatric liver transplantation

Molly O. Regelmann, Marina Goldis, Ronen Arnon

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

In the first five yr after liver transplant, approximately one in 10 pediatric recipients will develop NODAT. Factors associated with higher risk for NODAT have been difficult to identify due to lack of uniformity in reporting and data collection. Limited studies have reported higher risk in those who are at an older age at transplant, those with high-risk ethnic backgrounds, and in those with particular underlying conditions, such as CF and primary sclerosing cholangitis. Immunosuppressive medications, including tacrolimus, cyclosporine A, GC, and sirolimus, have been implicated as contributing to NODAT, to varying degrees. Identifying those at highest risk, appropriately screening, and diagnosing NODAT is critical to initiating timely treatment and avoiding potential complications. In the pediatric population, treatment is limited primarily to insulin, with some consideration for metformin. Children with NODAT should be monitored carefully for complications of DM, including microalbuminuria, hypertension, hyperlipidemia, and retinopathy.

Original languageEnglish (US)
Pages (from-to)452-459
Number of pages8
JournalPediatric Transplantation
Volume19
Issue number5
DOIs
StatePublished - Aug 1 2015
Externally publishedYes

Fingerprint

Liver Transplantation
Diabetes Mellitus
Pediatrics
Transplants
Sclerosing Cholangitis
Metformin
Tacrolimus
Sirolimus
Immunosuppressive Agents
Hyperlipidemias
Cyclosporine
Insulin
Hypertension
Liver
Therapeutics
Population

Keywords

  • insulin
  • liver transplant
  • new-onset diabetes after transplant
  • pediatric

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Transplantation

Cite this

New-onset diabetes mellitus after pediatric liver transplantation. / Regelmann, Molly O.; Goldis, Marina; Arnon, Ronen.

In: Pediatric Transplantation, Vol. 19, No. 5, 01.08.2015, p. 452-459.

Research output: Contribution to journalReview article

Regelmann, Molly O. ; Goldis, Marina ; Arnon, Ronen. / New-onset diabetes mellitus after pediatric liver transplantation. In: Pediatric Transplantation. 2015 ; Vol. 19, No. 5. pp. 452-459.
@article{0e452cbe263f4d0bac0539fffe62ba8b,
title = "New-onset diabetes mellitus after pediatric liver transplantation",
abstract = "In the first five yr after liver transplant, approximately one in 10 pediatric recipients will develop NODAT. Factors associated with higher risk for NODAT have been difficult to identify due to lack of uniformity in reporting and data collection. Limited studies have reported higher risk in those who are at an older age at transplant, those with high-risk ethnic backgrounds, and in those with particular underlying conditions, such as CF and primary sclerosing cholangitis. Immunosuppressive medications, including tacrolimus, cyclosporine A, GC, and sirolimus, have been implicated as contributing to NODAT, to varying degrees. Identifying those at highest risk, appropriately screening, and diagnosing NODAT is critical to initiating timely treatment and avoiding potential complications. In the pediatric population, treatment is limited primarily to insulin, with some consideration for metformin. Children with NODAT should be monitored carefully for complications of DM, including microalbuminuria, hypertension, hyperlipidemia, and retinopathy.",
keywords = "insulin, liver transplant, new-onset diabetes after transplant, pediatric",
author = "Regelmann, {Molly O.} and Marina Goldis and Ronen Arnon",
year = "2015",
month = "8",
day = "1",
doi = "10.1111/petr.12523",
language = "English (US)",
volume = "19",
pages = "452--459",
journal = "Pediatric Transplantation",
issn = "1397-3142",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - New-onset diabetes mellitus after pediatric liver transplantation

AU - Regelmann, Molly O.

AU - Goldis, Marina

AU - Arnon, Ronen

PY - 2015/8/1

Y1 - 2015/8/1

N2 - In the first five yr after liver transplant, approximately one in 10 pediatric recipients will develop NODAT. Factors associated with higher risk for NODAT have been difficult to identify due to lack of uniformity in reporting and data collection. Limited studies have reported higher risk in those who are at an older age at transplant, those with high-risk ethnic backgrounds, and in those with particular underlying conditions, such as CF and primary sclerosing cholangitis. Immunosuppressive medications, including tacrolimus, cyclosporine A, GC, and sirolimus, have been implicated as contributing to NODAT, to varying degrees. Identifying those at highest risk, appropriately screening, and diagnosing NODAT is critical to initiating timely treatment and avoiding potential complications. In the pediatric population, treatment is limited primarily to insulin, with some consideration for metformin. Children with NODAT should be monitored carefully for complications of DM, including microalbuminuria, hypertension, hyperlipidemia, and retinopathy.

AB - In the first five yr after liver transplant, approximately one in 10 pediatric recipients will develop NODAT. Factors associated with higher risk for NODAT have been difficult to identify due to lack of uniformity in reporting and data collection. Limited studies have reported higher risk in those who are at an older age at transplant, those with high-risk ethnic backgrounds, and in those with particular underlying conditions, such as CF and primary sclerosing cholangitis. Immunosuppressive medications, including tacrolimus, cyclosporine A, GC, and sirolimus, have been implicated as contributing to NODAT, to varying degrees. Identifying those at highest risk, appropriately screening, and diagnosing NODAT is critical to initiating timely treatment and avoiding potential complications. In the pediatric population, treatment is limited primarily to insulin, with some consideration for metformin. Children with NODAT should be monitored carefully for complications of DM, including microalbuminuria, hypertension, hyperlipidemia, and retinopathy.

KW - insulin

KW - liver transplant

KW - new-onset diabetes after transplant

KW - pediatric

UR - http://www.scopus.com/inward/record.url?scp=84933279019&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84933279019&partnerID=8YFLogxK

U2 - 10.1111/petr.12523

DO - 10.1111/petr.12523

M3 - Review article

C2 - 26032592

AN - SCOPUS:84933279019

VL - 19

SP - 452

EP - 459

JO - Pediatric Transplantation

JF - Pediatric Transplantation

SN - 1397-3142

IS - 5

ER -